Relmada Therapeutics Registers Over 33 Million Shares for Resale Following $160M Private Placement
Summary
Relmada Therapeutics filed an S-3 to register 33.68 million shares for resale by investors who participated in a recent $160 million private placement, enabling them to sell shares previously issued to resolve the company's going concern status.
Key Events · Financing and Capital Events · RLMD
-
Resale Registration Filed
Relmada Therapeutics filed an S-3 registration statement for the resale of up to 33,685,096 shares of common stock by selling stockholders.
-
Follows $160 Million Private Placement
These shares were issued in a private placement that closed on March 11, 2026, raising approximately $160 million for the company. The private placement shares were sold at $4.75 per share for common stock and $4.749 for pre-funded warrants.
-
Significant Market Overhang
The registered shares represent approximately 32.11% of the company's outstanding common stock, creating a substantial overhang as these shares become freely tradable.
-
No Direct Proceeds to Company
The company will not receive any proceeds from the sale of shares by the selling stockholders, as this filing is solely for their resale.
Analysis · RLMD · Life Sciences
This S-3 filing registers 33.68 million shares of common stock for resale by selling stockholders, stemming from a $160 million private placement that closed on March 11, 2026. While the company will not receive proceeds from these resales, this registration fulfills a prior agreement and makes these shares freely tradable. This event follows the company's recent announcement of securing $254 million in new financing to resolve its going concern status and advance its clinical pipeline. The registration of such a large block of shares (representing over 32% of outstanding shares) creates a significant market overhang, potentially impacting the stock price as investors gain the ability to sell.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLMD was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $733.2M. The 52-week trading range was $0.24 to $7.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.